Fore Biotherapeutics is focused on developing precision oncology treatments, particularly targeting patients with difficult-to-treat cancers that exhibit unaddressed mutations. Their lead program centers around plixorafenib, a next-generation BRAF inhibitor designed to effectively inhibit a broad spectrum of BRAF gene alterations in cancer cells. Unlike earlier BRAF inhibitors, plixorafenib is engineered to avoid the paradoxical activation of the RAF/MEK/ERK signaling pathway, which can occur with first-generation inhibitors. This unique mechanism allows plixorafenib to address acquired resistance to existing therapies, potentially leading to improved safety and more durable efficacy in treating various BRAF-driven tumors.

The company is currently conducting clinical trials to evaluate the efficacy and safety of plixorafenib in patients with advanced solid tumors harboring BRAF alterations. Preliminary results from these trials have shown promising anti-tumor activity, with a notable overall response rate in patients with BRAF-mutated cancers. Additionally, plixorafenib has received Orphan Drug and Fast Track designations from the FDA, underscoring its potential as a significant therapeutic option for patients who have exhausted prior treatment options. Through its innovative approach and commitment to addressing unmet medical needs, Fore Biotherapeutics aims to deliver high-impact therapies to patients facing challenging cancer diagnoses.

United States

Fore Biotherapeutics - We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our vision is to compassionately contribute to solving cancer.

Fore Biotherapeutics

Company Details